(CercleFinance.com) – Pfizer and BioNTech progress in unison this Friday on the New York Stock Exchange following the presentation of phase 2/3 clinical data demonstrating the effectiveness of their bivalent vaccine against the original Covid-19 virus and against the Omicron variant.
According to the two partners, a booster dose of 30 micrograms of this new vaccine generated a ‘robust’ immune response in study participants one month after the injection.
According to Pfizer and BioNTech, this bivalent vaccine allowed them to develop antibodies neutralizing the BA.4 and BA.5 Omicron subvariants about four times higher than the original vaccine in people over 55 years of age.
One month after the booster dose, neutralizing antibodies against Omicron BA.4/BA.5 were 13.2 times higher than pre-booster levels in adults over 55 years of age and 9.5 times higher in adults aged 18 to 55.
The two laboratories underline that these data reinforce the already favorable results observed one week after the injection of the booster dose.
Pfizer and BioNTech now say they want to share these findings with the US FDA and European Medicines Agency (FDA), as well as other international health agencies, as soon as possible.
Listed on the NYSE, the Pfizer stock rose 1.6% following this information, a performance in line with the S&P 500 index. Listed on the Nasdaq, the BioNTech stock climbed almost 7%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about Pfizer in real time: